Inmune Bio, Inc. (INMB)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$21.4M
Cash & Equivalents
$3.4M
Quarterly Burn Rate
19 mo
Est. Cash Runway
$52M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-06-23 8-K Inmune Bio, Inc. (INMB) (CIK 0001711754) - PRESS RELEASE DATED JUNE 23, 2026 EDGAR
2026-06-02 8-K Inmune Bio, Inc. (INMB) (CIK 0001711754) - PRESS RELEASE DATED JUNE 2, 2026 EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for INMB.

SEC EDGAR Filings

All SEC filings for Inmune Bio, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.